Dicerna CEO fears insider trading crackdown, withdraws own shares from Novo Nordisk offer

Douglas Fambrough, co-founder and current CEO of Dicerna, which recently received a USD 3.3bn acquisition offer by Novo Nordisk, no longer intends to offer his own shares as a part of the deal, fearing an insider trading crackdown.

Photo: POOL New/REUTERS / X80003

Novo Nordisk's cash tender offer to acquire all outstanding Dicerna shares no longer includes CEO Douglas Fambrough's personal shares, according to documents amending the original filing to the US Securities and Exchange Commission (SEC).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs